Senior Director
Merck, Inc
Dr. Younis is the cardiometabolic diseases therapeutic area lead in the Department of Quantitative Pharmacology and Pharmacometrics at Merck, Inc. .Islam started his career in the Office of Clinical Pharmacology, US Food and Drug Administration as reviewer and later became the Team Leader of the Antiviral Team and the Animal Rule Team. He also worked as Clinical Pharmacology Director and Senior Director at Astellas Pharma and Gilead Sciences, respectively. Dr. Younis is well known leader in the area of Clinical Pharmacology with numerous publications and presentations at national and international meetings. Dr. Younis is currently the Vice Chair of the IQ Clinical Pharmacology Leadership Group and the chair of the ASCPT Rare Disease Community. Islam is a pharmacist by training and hold MSc and PhD degrees is Pharmaceutical Sciences in addition to three graduate degrees in Public Health, Drug Development and Regulatory Sciences and Pharmacoepidemiology. He is also an adjunct Associate Professor at the George Washington University , School of Medicine.
Disclosure(s): Gilead Pharmaceuticals: Employment (Terminated, May 19, 2023); Merck & Co., Inc.: Employment (Ongoing)
Tuesday, March 26, 2024
8:30 AM – 5:30 PM MDT